Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Best in Class Continues to Perform
Tweet
Share
E-mailGet Alerts CPHD Hot Sheet
Price: $52.95 --0%
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Cepheid (NASDAQ: CPHD) price target of $45.00.
Canaccord analyst, Jeffrey Frelick, said, "We reiterate our rating following solid Q3 results that were slightly ahead of expectations. CPHD’s U.S. customers continue to increase their utilization with 40% using three tests or more."
"Flu could be meaningful. If the U.S experiences an average flu season we think CPHD will enjoy solid uptake of its new flu test, according to our previous hospital lab interviews."
For more ratings news on Cepheid click here and for the rating history of Cepheid click here.
Shares of Cepheid closed at $38.55 yesterday.
Canaccord analyst, Jeffrey Frelick, said, "We reiterate our rating following solid Q3 results that were slightly ahead of expectations. CPHD’s U.S. customers continue to increase their utilization with 40% using three tests or more."
"Flu could be meaningful. If the U.S experiences an average flu season we think CPHD will enjoy solid uptake of its new flu test, according to our previous hospital lab interviews."
For more ratings news on Cepheid click here and for the rating history of Cepheid click here.
Shares of Cepheid closed at $38.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
